In most cases, non-alcoholic fatty liver disease is associated with metabolic syndrome. Recent studies have linked the formation of metabolic disorders in the body, including non-alcoholic fatty liver disease, with impaired bowel microbiocenosis. The purpose of the study was to correct colon dysbiosis in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Material and methods. 52 patients with non-alcoholic fatty liver disease (specifically with non-alcoholic steatohepatitis) and type 2 diabetes mellitus were examined. All patients underwent general clinical, anthropometric, laboratory-instrumental methods of examination; qualitative and quantitative composition of the colon microflora was determined before and after treatment. In addition to complex therapy, patients were prescribed probiotic Opefera (2 capsules 3 times a day after meals for 4 weeks) for the correction of dysbiosis of large intestine. Results and discussion. Analysis of the microbial composition of fecal matter in the examined patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus before treatment indicated marked changes in the quantitative and qualitative composition of the microflora of the tissue. Decrease in the level of anaerobic flora was determined in all patients: bifidobacteria below 107 and lactobacilli below 106, which was accompanied by an increase in the number of pathogenic microflora in large intestine. After complex therapy with the use of the Opefera multiprobiotic in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus, we revealed positive dynamics in quantitative and qualitative composition of the microflora of large intestine. After the course of treatment with the use of Opefera, none of the examined patients was diagnosed with grade IV dysbiosis; grade III dysbiosis in these patients decreased 6-fold. These changes were accompanied by normalization in the microbial composition of large intestine in 21.2% of patients, as well as by an increase in the number of patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus with stage I dysbiosis (up to 38.5%). Conducted complex therapy also had a positive effect on lipid metabolism. Conclusion. Patients with non-alcoholic fatty liver disease (non-alcoholic steatohepatitis) and type 2 diabetes mellitus had large intenstine dysbiosis, mainly grade III and II. Complex therapy using multiperobiotic Opefera promotes the normalization of quantitative and qualitative composition of the microflora of large intestine in patients with non-alcoholic fatty liver disease (non-alcoholic steatohepatitis) and type 2 diabetes mellitus, as well as of the indicators of lipid metabolism in these patients.

Keywords: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes mellitus, colon dysbiosis, treatment

Full text: PDF (Ukr) 224K

1. Fadienko GD, Gridnyev AE Efficiency and safety of ademetionine in the correction of liver function in patients with steatohepatitis. The results of an open comparative post-marketing study. Gastroenterology. 2018; 52(2): 27-34. [Russian]
2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016; 64(6): 1388–402. https://www.ncbi.nlm.nih.gov/pubmed/27062661. https://doi.org/10.1016/j.jhep.2015.11.004
3. Ivaskin VT Diagnosis and treatment of nonalcoholic fatty liver disease: clinical recommendations. M: MED-press-inform; 2015. 32 р. [Russian]
4. Stepanov YuM, Nedzvetskaya NV, Yagmur VB, Klenina IA, Oshmyanskaya Nyu Noninvasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2017; 51(3): 188-95. https://doi.org/10.22141/2308-2097.51.3.2017.112635 [Ukrainian]
5. Buzzetti E, Pinzani M, Tsochatzis EA The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016; 65(8): 1038–48. https://www.ncbi.nlm.nih.gov/pubmed/26823198. https://doi.org/10.1016/j.metabol.2015.12.012
6. Satapati S, Sunny NE, Kucejova B, Fu X, He TT, Méndez-Lucas A, et al. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. Journal of Lipid Research. 2012; 53(6): 1080–92. https://www.ncbi.nlm.nih.gov/pubmed/22493093. https://www.ncbi.nlm.nih.gov/pmc/articles/3351815. https://doi.org/10.1194/jlr.M023382
7. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing MetaHIT Consortium. Nature. 2010; 464(7285): 59–65. https://www.ncbi.nlm.nih.gov/pubmed/20203603. https://www.ncbi.nlm.nih.gov/pmc/articles/3779803. https://doi.org/10.1038/nature08821